MedTrace Logo

Traditional Chinese Medicine or Low-dose Dexamethasone in COVID-19 Pneumonia

NCT05798195 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2023-04-04

No results posted yet for this study

Summary

The goal of this type of clinical trial is to learn about symptomatic patients with post-COVID-19 parenchymal lung abnormalities. The main questions it aims to answer are: the efficacy and safety of low-dose dexamethasone or traditional Chinese medicine in symptomatic patients with post-COVID-19 parenchymal lung abnormalities.

Participants will be divided into three parallel groups：controlled group with conventional western medicine treatment including oxygen therapy, antibiotics, nebulization therapy, etc. dexamethasone group: dexamethasone 1.5mg/day for one week and 0.75mg/day for another week basing on conventional western medicine. Chinese medicine group: Strengthening spleen and tonifying lung decoction for 2 weeks basing on conventional western medicine.

Conditions

Interventions

OTHER

conventional western medicine treatment

conventional western medicine treatment only

DRUG

Dexamethasone oral tablet

treat with Dexamethasone for 2 weeks

OTHER

Traditional Chinese medicine decoction

treat with strengthening spleen and tonifying lung decoction for 2 weeks

Sponsors & Collaborators

  • China-Japan Friendship Hospital

    lead OTHER

Principal Investigators

  • Zhenguo Zhai, Dcotor · Department of Respiratory and Critical Care Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05798195 on ClinicalTrials.gov